

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

MG-63

RRID:CVCL_0426

Type: Cell Line

Proper Citation

RRID:CVCL_0426

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0426

Proper Citation: RRID:CVCL_0426

Description: Cell line MG-63 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Osteosarcoma

Defining Citation: [PMID:218153](#), [PMID:883813](#), [PMID:1577731](#), [PMID:2233717](#), [PMID:2823272](#), [PMID:7873286](#), [PMID:8617485](#), [PMID:9144345](#), [PMID:9600771](#), [PMID:12645653](#), [PMID:15736406](#), [PMID:17981215](#), [PMID:19160414](#), [PMID:19363654](#), [PMID:19787792](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21519327](#), [PMID:22460905](#), [PMID:23129384](#), [PMID:23144859](#), [PMID:24903274](#), [PMID:25382592](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26320182](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29334376](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#), [PMID:36480329](#)

Comments: Caution: The reported STR profile from CLS of this cell line was changed in June 2019. Seven conflicts with other sources were resolved., Anecdotal: Have been flown in space on Foton-10 and Foton-M3 to study if differentiation is altered in microgravity (PubMed=9144345; PubMed=9600771; PubMed=24903274)., Characteristics: Can be induced to differentiate by treating the cells with 1,25-dihydroxyvitamin D3 and TGF-beta. The cells do not differentiate into the mineralized state, but stop at the matrix maturation stage (PubMed=1577731)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Space-flown cell line (cellonaut).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MG-63

Synonyms: M-G63, MG63

Cross References: BTO:BTO_0001596, CLO:CLO_0007699, CLO:CLO_0007701, CLO:CLO_0050808, EFO:EFO_0002234, MCCL:MCC:0000323, CLDB:cl3462, CLDB:cl3463, CLDB:cl3464, CLDB:cl3465, CLDB:cl4934, AddexBio:C0004007/4991, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1427, BCRC:60279, BCRJ:0173, BioSample:SAMN03471910, BioSample:SAMN03472771, BioSample:SAMN10988146, cancercellines:CVCL_0426, CCRID:1101HUM-PUMC000080, CCRID:3101HUMTCHu124, CCRID:4201HUM-CCTCC00074, CCTCC:GDC0074, Cell_Model_Passport:SIDM00525, ChEMBL-Cells:ChEMBL3308498, ChEMBL-Targets:ChEMBL614347, CLS:300441, Cosmic:755310, Cosmic:908131, Cosmic:931036, Cosmic:931913, Cosmic:1044085, Cosmic:1070844, Cosmic:1074394, Cosmic:1082504, Cosmic:1188475, Cosmic:1529903, Cosmic-CLP:908131, DepMap:ACH-000359, ECACC:86051601, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS091SUW, ENCODE:ENCBS462PMF, GDSC:908131, GEO:GSM170251, GEO:GSM320828, GEO:GSM827317, GEO:GSM879217, GEO:GSM887314, GEO:GSM888390, GEO:GSM1670103, GEO:GSM1915004, GEO:GSM1915005, GEO:GSM1915006, GEO:GSM1915007, GEO:GSM1915033, GEO:GSM1915034, GEO:GSM2635311, GEO:GSM2635312, IARC_TP53:21498, IARC_TP53:21660, ICLC:HTL99003, IGRhCellID:MG63, IZSLER:BS TCL 40, JCRB:IFO50108, KCB:KCB 200528YJ, KCLB:21427, LiGeA:CCLE_145, LINCS_LDP:LCL-1428, Lonza:872, NCBI_Iran:C555, PharmacDB:MG63_924_2019, PRIDE:PXD030304, Progenetix:CVCL_0426, PubChem_Cell_line:CVCL_0426, RCB:RCB1890, TKG:TKG 0294, TOKU-E:2429, Wikidata:Q54905408

ID: CVCL_0426

Record Creation Time: 20220427T220805+0000

Record Last Update: 20260905T181139+0000

Ratings and Alerts

No rating or validation information has been found for MG-63.

No alerts have been found for MG-63.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2532 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Yao J, et al. (2026) Design of Safe and Efficient Adenine Base Editors via Protein Language Model Screening for Osteoarthritis Treatment. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(30), e19807.

Tao Y, et al. (2026) TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. *Cancer research*, 86(9), 2161.

Wang J, et al. (2026) Prognostic characteristics of disulfidptosis-related genes across cancers and their potential implications in osteosarcoma. *Science progress*, 109(2), 368504261464856.

Kooi R, et al. (2026) Controllable Dynamic Mechanical Cell Stimulation using Magnetically Actuated Artificial Cilia. *Advanced healthcare materials*, 15(18), e00001.

Zhang Y, et al. (2026) CPSF2-mediated 3' UTR truncation of MTERF3 drives mitochondrial dysfunction and osteosarcoma progression. *Oncogene*, 45(28), 2851.

Aderhold N, et al. (2026) Combined Inhibition of ATR and Ribonucleotide Reductase Induces Synergistic Antineoplastic Activity in Osteosarcoma Cells. *Cancer reports* (Hoboken, N.J.), 9(5), e70568.

Solern?? LM, et al. (2026) Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma. *Frontiers in medicine*, 13, 1864843.

Bai G, et al. (2026) LARS promotes osteosarcoma proliferation through leucine-dependent PRIM2 translation and DNA replication activation. *Journal of experimental & clinical cancer research : CR*, 45(1).

Peng M, et al. (2026) In vitro modeling of nutritional and mitochondria-targeted therapies for osteosarcoma. *bioRxiv : the preprint server for biology*.

Ivanov P, et al. (2025) Development and validation of the Azu-Eos as a fluorescence-free staining method for enhanced bright-field microscopy in the comet assay. *Methods* (San Diego, Calif.), 241, 103.

Panda PK, et al. (2025) BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation-Induced Apoptosis. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1333.

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(18), 3864.

Yagnik D, et al. (2025) Annona muricata Graviola Induces Apoptosis in Two Osteosarcoma Cell Lines and Downregulates the Cytokines IL-6 and TGF??1 Which Are Implicated in Tumour Growth and Metastasis. *Integrative cancer therapies*, 24, 15347354251360338.

Takami H, et al. (2025) LAT1-Targeted Alpha Therapy Using 211At-AAMT for Bone and Soft Tissue Sarcomas. *International journal of molecular sciences*, 26(17).

Ozaki K, et al. (2025) Annexin A1-Targeted d-Peptide-Monomethyl Auristatin E Conjugate Enhanced Antitumor Effect of Monomethyl Auristatin E for Chemotherapy of Prostate Cancer. *The Prostate*, 85(13), 1208.

Zhao T, et al. (2025) Derepressing nuclear pyruvate dehydrogenase induces therapeutic cancer cell reprogramming. *Cell metabolism*, 37(8), 1667.

Yang Y, et al. (2025) Multi-omics Analysis of Histone-related Genes in Osteosarcoma: A Multidimensional Integrated Study Revealing Drug Sensitivity and Immune Microenvironment Characteristics. *Technology in cancer research & treatment*, 24, 15330338251336275.

Kim D, et al. (2025) TRIM24 directs replicative stress responses to maintain ALT telomeres via chromatin signaling. *Molecular cell*, 85(14), 2636.

Dai C, et al. (2025) Pharmacologic inhibition of CSF-1R suppresses intrinsic tumor cell growth in osteosarcoma with CSF-1R overexpression. *Journal of translational medicine*, 23(1), 900.

Jing D, et al. (2025) Transketolase promotes osteosarcoma progression through the YY1-PAK4 axis. *The FEBS journal*, 292(7), 1798.